SHUKLA SANJAY (President and CEO) purchased 24.5% of their position (15K shares) of ATYR PHARMA INC on the open market
Open‑market purchase worth $30.2K — a significant purchase. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 8/1/2023ACC: 0001209191-23-043943
Officer· President and CEO
Since Feb 2019
+15K
Net shares
Net buyer
$30.2K
Total acquired
1
Open market trades
1B · 0S
1
Total transactions
15K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+15K
Price / share
$2.01
Trade value
$30.22K
% of position
24.5%
7/28/2023
61.17K→76.17K
Total
Net shares
+15K
Net value
$30.22K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 7/28/2023 | P · Purchase | +15K | $2.01 | $30.22K | 24.5% | 61.17K | 76.17K |
| Total | +15K | $30.22K | ||||||
Derivative Transactions0
No derivative transactions reported